Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00081159
Status:
COMPLETED
Last Update Posted:
2016-11-10
First Post:
2004-04-07
Brief Title:
Hormone Ablation Therapy Doxorubicin and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
A Randomized Phase II Study Of Bone-Targeted Therapy In Advanced Androgen-Dependent Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Androgens can stimulate the growth of prostate cancer cells Drugs such as goserelin and leuprolide may fight prostate cancer by stopping the adrenal glands from producing androgens Drugs used in chemotherapy such as doxorubicin work in different ways to stop tumor cells from dividing so they stop growing or die Zoledronate may prevent bone loss and stop the growth of tumor cells in bone Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer It is not yet known whether hormone androgen ablation therapy and chemotherapy combined with zoledronate is more effective with or without strontium-89 in treating prostate cancer and bone metastases
PURPOSE This randomized phase II trial is studying giving hormone ablation therapy doxorubicin and zoledronate together with strontium-89 to see how well it works compared to hormone ablation therapy doxorubicin and zoledronate alone in treating patients with androgen-dependent prostate cancer and bone metastases
PURPOSE This randomized phase II trial is studying giving hormone ablation therapy doxorubicin and zoledronate together with strontium-89 to see how well it works compared to hormone ablation therapy doxorubicin and zoledronate alone in treating patients with androgen-dependent prostate cancer and bone metastases
Detailed Description:
OBJECTIVES
Primary
Compare the clinical efficacy of hormonal ablative therapy combined with doxorubicin and zoledronate with or without strontium chloride Sr 89 in terms of progression-free survival in patients with androgen-dependent prostate cancer and bone metastases
OUTLINE This is a randomized multicenter study Patients are stratified according to the number of bony metastases 6 versus 6 Patients are randomized to 1 of 2 treatment arms
Arm I Patients receive hormonal ablative therapy comprising luteinizing hormone-releasing hormone agonist eg leuprolide or goserelin continuously during study treatment OR bilateral orchiectomy Patients also receive doxorubicin intravenously IV on days 1 8 and 15 every 28 days for 2 courses zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses and a single dose of strontium chloride Sr 89 IV over 1-2 minutes on day 1
Arm II Patients receive hormonal ablative therapy doxorubicin and zoledronate as in arm I
In both arms treatment continues in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months
PROJECTED ACCRUAL A total of 80 patients 40 per treatment arm will be accrued for this study within 20 months
Primary
Compare the clinical efficacy of hormonal ablative therapy combined with doxorubicin and zoledronate with or without strontium chloride Sr 89 in terms of progression-free survival in patients with androgen-dependent prostate cancer and bone metastases
OUTLINE This is a randomized multicenter study Patients are stratified according to the number of bony metastases 6 versus 6 Patients are randomized to 1 of 2 treatment arms
Arm I Patients receive hormonal ablative therapy comprising luteinizing hormone-releasing hormone agonist eg leuprolide or goserelin continuously during study treatment OR bilateral orchiectomy Patients also receive doxorubicin intravenously IV on days 1 8 and 15 every 28 days for 2 courses zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses and a single dose of strontium chloride Sr 89 IV over 1-2 minutes on day 1
Arm II Patients receive hormonal ablative therapy doxorubicin and zoledronate as in arm I
In both arms treatment continues in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months
PROJECTED ACCRUAL A total of 80 patients 40 per treatment arm will be accrued for this study within 20 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MDA-2003-0922 | None | None | None |
| NCI-6459 | None | None | None |
| NCI-2009-00062 | REGISTRY | None | None |
| CDR0000360625 | OTHER | None | None |
| 2U10CA045809-17 | NIH | NCI | httpsreporternihgovquickSearch2U10CA045809-17 |